Key result
Placement of an ameroid constrictor on the LAD in mini-swine caused a 50% reduction in ejection fraction and revealed NADH-mediated energy metabolism disorders underlying chronic heart failure.
A new mini-swine model of chronic progressive heart failure using an LAD ameroid constrictor reveals NADH-mediated energy metabolism disorders as key pathophysiological mechanisms.
Supports NADH metabolism as HF research target; leaves open clinical translation from this animal model.
BACKGROUND: Despite major advances in the treatment of heart failure (HF), it remains the major cause of mortality and morbidity worldwide. Experimental models of HF typically utilize acute myocardial infarction. However, the majority of clinical HFs occur gradually by a chronic progressive mechanism. Thus, more relevant models are required to aid identification, quantification, and characterization of HF, and its underlying mechanisms. METHODS AND FINDINGS: We developed a model of progressive chronic heart failure (CHF) in the mini-swine by placement of an ameroid constrictor on the left anterior descending coronary artery (LAD). This model demonstrated a steady decline in the cardiac function from 8 to 12 weeks, with a 50% reduction in the ejection fraction. Further, the proteomic, metabolomic and bioinformatic analyses of ischemic tissue and plasma revealed a significant alteration of the mitochondrial respiratory chain mediated by nicotinamide adenine dinucleotide (NADH), which resulted in down-regulation of malate dehydrogenase (MDH) and insufficient energy supply to support cardiac contractility and relaxation. Furthermore, significant changes in apolipoprotein A-I, low density lipoprotein (LDL), and very LDL (VLDL) in plasma indicated that lipid metabolism disorders occurred in mini-swines with myocardial ischemia via glycerolipid metabolism. CONCLUSIONS: We describe a stable and easily reproducible CHF model using an ameroid constrictor placed on the LAD. We found that the NADH-mediated tricarboxylic acid cycle and energy metabolism disorders are key pathophysiological mechanisms underlying CHF. These data will provide potential biomarkers for monitoring the therapeutic intervention of CHF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) studied Chronic progressive heart failure. Ameroid constrictor on the left anterior descending coronary artery was evaluated on Cardiac function and proteomic/metabolomic alterations. Placement of an ameroid constrictor on the LAD in mini-swine caused a 50% reduction in ejection fraction and revealed NADH-mediated energy metabolism disorders underlying chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: